These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 7526215

  • 41. Hepatitis C virus transmission by intravenous immunoglobulin.
    Yap PL, McOmish F, Webster AD, Hammarstrom L, Smith CI, Bjorkander J, Ochs HD, Fischer SH, Quinti I, Simmonds P.
    J Hepatol; 1994 Sep; 21(3):455-60. PubMed ID: 7836718
    [Abstract] [Full Text] [Related]

  • 42. HCV infection in patients with primary defects of immunoglobulin production.
    Quinti I, Pandolfi F, Paganelli R, el Salman D, Giovannetti A, Rosso R, Oliva A, Rainaldi L, Aiuti F.
    Clin Exp Immunol; 1995 Oct; 102(1):11-6. PubMed ID: 7554376
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Hepatitis C and immune globulin.
    Douglas SD, Slade HB.
    N Engl J Med; 1995 May 04; 332(18):1235; author reply 1236-7. PubMed ID: 7700323
    [No Abstract] [Full Text] [Related]

  • 45. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre.
    Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, Muss N, Sandhofer F, Vogel W.
    Gut; 1999 Apr 04; 44(4):563-7. PubMed ID: 10075966
    [Abstract] [Full Text] [Related]

  • 46. Hepatitis C virus transmission by intravenous immunoglobulin.
    Farrugia A, Walker E.
    Lancet; 1995 Aug 05; 346(8971):373; author reply 374-5. PubMed ID: 7542718
    [No Abstract] [Full Text] [Related]

  • 47. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.
    Lawlor E, Columb G.
    N Engl J Med; 1999 Sep 02; 341(10):762; author reply 763. PubMed ID: 10475797
    [No Abstract] [Full Text] [Related]

  • 48. Transmission rates of hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation.
    Lawlor E, Power J, Garson J, Yap P, Davidson F, Columb G, Smith D, Pomeroy L, O'Riordan J, Simmonds P, Tedder R.
    Vox Sang; 1999 Sep 02; 76(3):138-43. PubMed ID: 10341327
    [Abstract] [Full Text] [Related]

  • 49. Laboratory diagnosis and molecular epidemiology of an outbreak of hepatitis C virus infection among recipients of human intravenous immunoglobulin in Spain.
    Echevarría JM, León P, Domingo CJ, López JA, Elola C, Madurga M, Salmerón F, Yap PL, Daub J, Simmonds P.
    Transfusion; 1996 Aug 02; 36(8):725-30. PubMed ID: 8780668
    [Abstract] [Full Text] [Related]

  • 50. Prevalence of hepatitis C in patients with primary antibody deficiency.
    Webster AD, Brown D, Franz A, Dusheiko G.
    Clin Exp Immunol; 1996 Jan 02; 103(1):5-7. PubMed ID: 8565286
    [Abstract] [Full Text] [Related]

  • 51. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency.
    Björkander J, Cunningham-Rundles C, Lundin P, Olsson R, Söderström R, Hanson LA.
    Am J Med; 1988 Jan 02; 84(1):107-11. PubMed ID: 3122562
    [Abstract] [Full Text] [Related]

  • 52. Effect of immune globulin on the prevention of experimental hepatitis C virus infection.
    Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, Kuo G, Spelbring JE, Meeks E, Sinha S, Carson DA.
    J Infect Dis; 1996 Apr 02; 173(4):822-8. PubMed ID: 8603959
    [Abstract] [Full Text] [Related]

  • 53. A second outbreak of hepatitis C virus infection from anti-D immunoglobulin in Ireland.
    Smith DB, Lawlor E, Power J, O'Riordan J, McAllister J, Lycett C, Davidson F, Pathirana S, Garson JA, Tedder RS, Yap PL, Simmonds P.
    Vox Sang; 1999 Apr 02; 76(3):175-80. PubMed ID: 10341334
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
    Yei S, Yu MW, Tankersley DL.
    Transfusion; 1992 Apr 02; 32(9):824-8. PubMed ID: 1335184
    [Abstract] [Full Text] [Related]

  • 57. [Interferon treatment of type C fulminant hepatitis].
    Yoshiba M, Inoue K, Sekiyama K.
    Nihon Rinsho; 1994 Jul 02; 52(7):1857-64. PubMed ID: 7521431
    [Abstract] [Full Text] [Related]

  • 58. Non-A non-B hepatitis and the safety of intravenous immune globulin, pH 4.2: a retrospective survey. Preliminary communication.
    Rousell RH, Good RA, Pirofsky B, Schiff RI.
    Vox Sang; 1988 Jul 02; 54(1):6-13. PubMed ID: 3126601
    [Abstract] [Full Text] [Related]

  • 59. Hepatitis C virus infection: clinical aspects and treatment with interferon alfa.
    Jonas MM.
    Clin Ther; 1996 Jul 02; 18 Suppl B():110-25. PubMed ID: 8930449
    [Abstract] [Full Text] [Related]

  • 60. Hepatitis C virus liver disease in women infected with contaminated anti-D immunoglobulin.
    Sheehan MM, Doyle CT, Whelton M, Kenny-Walsh E.
    Histopathology; 1997 Jun 02; 30(6):512-7. PubMed ID: 9205854
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.